Abstract
Tuberculosis (TB) killed more people globally than any other single pathogen over the past decade. Where surveillance is weak, estimating TB burden estimates uses modeling. In many African countries, increases in HIV prevalence and antiretroviral therapy (ART) have driven dynamic TB epidemics, complicating estimation of burden, trends, and potential intervention impact. We therefore developed a novel age-structured TB transmission model incorporating evolving demographic and HIV/ART effects, and calibrated to TB prevalence and notification data from 12 African countries. We used Bayesian methods to include uncertainty for all TB model parameters, and estimated age-specific annual risks of TB infection (ARTI) and proportion of TB incidence from recent (re)infection (PR). We found ARTI of up to 16.0%/year in adults, but a mean PR across countries of 34%. Rapid reduction of the unacceptably high burden of TB in high HIV prevalence settings will require interventions addressing progression as well as transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by an MRC fellowship to PJD (MR/P022081/1) and by the TREATS study (RIA2016S-1632-TREATS); part of the EDCTP2 programme supported by the European Union. This research was funded in whole, or in part, by the Wellcome Trust [206575/Z/17/Z]. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. TC, PM, and PJD were supported by US NIH R01 R01AI147854.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code are available at https://github.com/petedodd/estevez
